Our facilities
Our R&D and manufacturing facilities located in US, UK and India are built to global standards and cater to an international set of clients. Several new facilities are planned for the near future and existing ones are expanding with state-of-the-art blocks. Our headquarters are in Hyderabad, right in the middle of India. We pride ourselves in a global reach.
Discovery Biology Lab, Greater Boston, USA
Sai Life Sciences' discovery biology facility provides exploratory biology services to the expanding array of start-up and biotech companies in the Boston area and to companies in North America. It enables opportunities for companies to have face-to-face collaborations with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle times.
Read more
Integrated campus, Hyderabad
The Integrated Discovery & Development Campus (Unit II) enables us to provide scientific solutions and supports a comprehensive suite of services, ranging from early-phase discovery, preclinical development, and clinical development, through to commercial manufacturing. This 12-acre campus in Hyderabad serves our customers globally, ensuring a seamless integration of all phases of drug development cycle.
Read more
Process R&D Lab, Manchester, UK
Sai Life Sciences' Process R&D laboratory at Alderley Park, Manchester, UK serves as a centre of excellence for Process and Analytical Development to the expanding list of global clients, adding value to their NCE small molecule development programs.
Read more
API Manufacturing Facility, Bidar, India
Sai Life Sciences’ flagship manufacturing centre (Unit IV) delivers cGMP API and intermediates for early phase, late phase and commercial molecules across US, Europe and Japan.
Read more
In addition to the above-mentioned facilities, we also have an intermediate manufacturing plant (Unit III Bollaram Facility) with 44 kL of reactor capacity in Bollaram near Hyderabad, India. The Unit VI Bidar Facility, together with the HPAPI block in Unit IV will enable us to cater to the oncology API market.